BIOA (BioAge Labs, Inc) Total Enterprise Value

BioAge Labs, Inc - graphic logo of issuer BIOA

BioAge Labs, Inc. (BIOA) ensures production stability by establishing an extensive component supply chain. Simultaneously, the company is researching aging processes to develop therapies for metabolic disorders. This price chart shows that the company's valuation is -64.86. The technology stack is further enhanced by the implementation of robotic systems and AI services for the precise identification of molecular targets.

BIOA (bioagelabs.com) Total Company Value history from 11/23/2025 to 10/28/2026

BioAge Labs, Inc. (BIOA) - metric breakdowns and financial figures

- price and consensus price forecast:
Market Chart BioAge Labs|BIOA - Price Target Chart
- market capitalization data:
Market Value BioAge Labs, Inc.|BIOA - Enterprise Value
- book capitalization data:
Book Value per Share BioAge Labs, Inc.|BIOA - Company Book Value|Market Capitalization to Net Assets bioagelabs.com|BIOA - Company Total Assets
- debt and liquidity data:
All Debt to Shareholders' Equity Ratio BioAge Labs, Inc.|BIOA - Long-Term Debt to Capital|Short-Term Debt to Capital bioagelabs.com|BIOA - Company Debts|Debt to Net Assets Ratio BioAge Labs, Inc.|BIOA - Company Long-Term Debt|Company Current Liabilities BioAge Labs, Inc.
Comprehensive company analysis:BioAge Labs (BIOA)
Original product of BioAge Labs, Inc.

BioAge Labs, Inc. (BIOA) development of incretin mimetics and its partnership with Eli Lilly position the company as a strategic asset in the longevity sector. The current market valuation of assets, excluding liquidity, at -64.86, aggregates capitalization and net debt to determine the actual business buyout value. The dynamics of this indicator allow investors to assess the stability of the company's capital relative to its fundamental value amid volatility.

Competitor analysis for BioAge Labs, Inc.

Ascendis Pharma AS - Company Buyout Price|MDGL (Madrigal Pharma) - Total Company Value|CORT - Total Enterprise Value|RYTM: Enterprise Value|AKRO (akerotx.com) - Enterprise Value|Total Company Value Metsera MTSR|Full Business Value MoonLake Immunotherapeutics AG|Crinetics Pharma (CRNX) - Enterprise Value|Value Adjusted for Debt and Cash NewAmsterdam Pharma Corp (NAMS)|Enterprise Value SLNO (Soleno Therapeutics)|amicusrx.com - Enterprise Value|Total Company Value 89bio (ETNB)|AGIO: Value Adjusted for Debt and Cash|GPCR (Structure Pharma) - Total Company Value|MiMedx Corp (MDXG) - Real Price to Acquire Entire Company|RZLT (Rezolute, Inc.) - Enterprise Value|Enterprise Value lexpharma.com (LXRX)|MBX Biosciences (MBX) - Real Price to Acquire Entire Company|Value Adjusted for Debt and Cash ALT (Altimmune Inc)|Aardvark Therapeutics Corp - Total Company Value|Real Price to Acquire Entire Company Sagimet Biosciences Inc SGMT|BMEA (Biomea Fusion, Inc.) - Enterprise Value|Quince Therapeutics (QNCX) - Total Enterprise Value|GUTS - Real Price to Acquire Entire Company|vTv Therapeutics (VTVT) - Aggregate Business Value|ATPC (Agape ATP Corp) - Enterprise Value|Enterprise Value Pluri Inc|Enterprise Value Synlogic, Inc. (SYBX)|Total Company Value LPCN (lipocine.com)|MTNB: Total Company Value|sprucebiosciences.com - Total Enterprise Value|GLTO - Total Company Value|CTCX - Total Company Value|Lumos Pharma, Inc. - Enterprise Value|ONVO (organovo.com) - Company Buyout Price|RDUS: Total Company Value